HIV Subtypes and Drug-resistance-associated Mutations in US Blood Donors, 2015-2020.

HIV blood donors blood screening genetic sequence analysis phylogenetics

Journal

Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045

Informations de publication

Date de publication:
Jul 2024
Historique:
received: 02 04 2024
accepted: 14 06 2024
medline: 12 7 2024
pubmed: 12 7 2024
entrez: 12 7 2024
Statut: epublish

Résumé

Monitoring genotypes of HIV infections in blood donors may provide insights into infection trends in the general population. HIV RNA was extracted from plasma samples of blood donors confirmed as HIV positive by blood screening nucleic acid and antibody tests. HIV genome target regions were amplified using nested real time-polymerase chain reaction followed by next-generation sequencing. Sequences were compared to those in the Los Alamos National Laboratory (LANL) database. Sequences were also assessed for drug resistance mutations (DRM) using the Stanford HIV DRM Database. From available HIV-positive donations collected between 1 September 2015 and 31 December 2020, 563 of 743 (75.8%) were successfully sequenced; 4 were subtype A, 543 subtype B, 5 subtype C, 1 subtype G, 5 circulating recombinant forms (CRF), and 2 were subtype B and D recombinants. Overall, no significant differences between blood donor and available LANL genotypes were found, and the genotypes of newly acquired versus prevalent HIV infections in donors were similar. The proportion of non-B subtypes and CRF remained a small fraction, with no other subtype or CRF representing more than 1% of the total. DRM were identified in 122 (21.6%) samples with protease inhibitor, nucleoside reverse transcriptase inhibitor and non-nucleoside reverse transcriptase inhibitor DRMs identified in 4.9%, 4.6% and 14.0% of samples, respectively. HIV genetic diversity and DRM in blood donors appear representative of circulating HIV infections in the US general population and may provide more information on infection diversity than sequences reported to LANL, particularly for recently transmitted infections.

Sections du résumé

Background UNASSIGNED
Monitoring genotypes of HIV infections in blood donors may provide insights into infection trends in the general population.
Methods UNASSIGNED
HIV RNA was extracted from plasma samples of blood donors confirmed as HIV positive by blood screening nucleic acid and antibody tests. HIV genome target regions were amplified using nested real time-polymerase chain reaction followed by next-generation sequencing. Sequences were compared to those in the Los Alamos National Laboratory (LANL) database. Sequences were also assessed for drug resistance mutations (DRM) using the Stanford HIV DRM Database.
Results UNASSIGNED
From available HIV-positive donations collected between 1 September 2015 and 31 December 2020, 563 of 743 (75.8%) were successfully sequenced; 4 were subtype A, 543 subtype B, 5 subtype C, 1 subtype G, 5 circulating recombinant forms (CRF), and 2 were subtype B and D recombinants. Overall, no significant differences between blood donor and available LANL genotypes were found, and the genotypes of newly acquired versus prevalent HIV infections in donors were similar. The proportion of non-B subtypes and CRF remained a small fraction, with no other subtype or CRF representing more than 1% of the total. DRM were identified in 122 (21.6%) samples with protease inhibitor, nucleoside reverse transcriptase inhibitor and non-nucleoside reverse transcriptase inhibitor DRMs identified in 4.9%, 4.6% and 14.0% of samples, respectively.
Conclusions UNASSIGNED
HIV genetic diversity and DRM in blood donors appear representative of circulating HIV infections in the US general population and may provide more information on infection diversity than sequences reported to LANL, particularly for recently transmitted infections.

Identifiants

pubmed: 38994445
doi: 10.1093/ofid/ofae343
pii: ofae343
pmc: PMC11237352
doi:

Types de publication

Journal Article

Langues

eng

Pagination

ofae343

Investigateurs

E Notari (E)
S Stramer (S)
R Dodd (R)
G Conti (G)
R Fayed (R)
D Nelson (D)
R Townsend (R)
G Foster (G)
J Haynes (J)
E Crawford (E)
E Huseynova (E)
D Krysztof (D)
D Burke (D)
M Lanteri (M)
V Green (V)
S Cyrus (S)
P Williamson (P)
D Kessler (D)
J Gorlin (J)
L Milan-Benson (L)
C DelValle (C)
P Chien (P)
T Brown (T)
R Reik (R)
C Shea (C)
M Lopez (M)
K Richards (K)
T Foster (T)
J Brodsky (J)
M Barr (M)
T Rains (T)
B Custer (B)
R Bruhn (R)
E Grebe (E)
M Busch (M)
M Stone (M)
C Di Germanio (C)
D Hindes (D)
Z Kaidarova (Z)
K Zurita (K)
A Tadena (A)
L Montalvo (L)
A Dayana (A)
S Hughes (S)
M Townsend (M)
M Bravo (M)
J Vannoy (J)
S Fallon (S)
S Anderson (S)
B Whitaker (B)
H Yang (H)
A Belov (A)
A Eder (A)
B Hailu (B)
S Zou (S)
J Berger (J)
Brian Custer (B)
Susan Stramer (S)
Debra Kessler (D)
Rita Reik (R)
Phillip Williamson (P)
Steven A Anderson (SA)
Benyam Hailu (B)

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Déclaration de conflit d'intérêts

Potential conflicts of interest. The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

Auteurs

Brian Custer (B)

Vitalant Research Institute, San Francisco, California, USA.
Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA.

Eda Altan (E)

Vitalant Research Institute, San Francisco, California, USA.

Leilani Montalvo (L)

Vitalant Research Institute, San Francisco, California, USA.

Alison Coyne (A)

Vitalant Research Institute, San Francisco, California, USA.

Eduard Grebe (E)

Vitalant Research Institute, San Francisco, California, USA.

Xutao Deng (X)

Vitalant Research Institute, San Francisco, California, USA.
Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA.

Mars Stone (M)

Vitalant Research Institute, San Francisco, California, USA.
Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA.

Eric Delwart (E)

Vitalant Research Institute, San Francisco, California, USA.
Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA.

Sonia Bakkour (S)

Global Medical Affairs Donor Screening, Grifols Diagnostic Solutions, Emeryville, California, USA.

Benyam Hailu (B)

Division of Blood Diseases and Resources, National Heart, Lung, and Blood Institute, National Institutes of Health, Rockville, Maryland, USA.

Rita Reik (R)

Scientific, Medical, Technical and Research, OneBlood, St. Petersburg, Florida, USA.

Debra Kessler (D)

Medical Programs and Services, New York Blood Center, New York, New York, USA.

Susan L Stramer (SL)

Infectious Disease Consultant, North Potomac, Maryland, USA.

Michael P Busch (MP)

Vitalant Research Institute, San Francisco, California, USA.
Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA.

Classifications MeSH